Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1987 Aug;62(8):776–779. doi: 10.1136/adc.62.8.776

United Kingdom multicentre clinical trial of somatrem.

R D Milner 1, N D Barnes 1, J M Buckler 1, D J Carson 1, D R Hadden 1, I A Hughes 1, D I Johnston 1, J M Parkin 1, D A Price 1, P H Rayner 1, et al.
PMCID: PMC1778484  PMID: 3310915

Abstract

In a multicentre clinical trial 54 children aged 4.0 to 17.3 years, who had growth hormone deficiency that had not previously been treated, were given biosynthetic methionyl growth hormone (somatrem) 4 units three times a week by subcutaneous or intramuscular injection for one year. Height was measured every three months for at least one year before and during treatment. Forty two patients responded to treatment with an increase in growth of greater than 1.5 cm/year. The remaining 12 who grew more slowly were less obviously short and had a higher pretreatment growth than those who responded. The three who responded and the one who did not had undergone therapeutic spinal irradiation before starting the drug. If a whole year's pretreatment growth rate of less than 5 cm/year had been used as a diagnostic criterion the prediction of those who responded would have slightly improved. About two thirds of the patients developed antibodies against growth hormone and Escherichia coli protein; these were, however, of low and fluctuating titre and binding capacity, and did not influence the response to treatment. No adverse side effects were encountered. We conclude that somatrem is a safe and effective alternative to pituitary growth hormone.

Full text

PDF
779

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson R. Immunological aspects of human growth hormone. Acta Paediatr Scand Suppl. 1986;325:48–54. doi: 10.1111/j.1651-2227.1986.tb10364.x. [DOI] [PubMed] [Google Scholar]
  2. Flodh H. Human growth hormone produced with recombinant DNA technology: development and production. Acta Paediatr Scand Suppl. 1986;325:1–9. doi: 10.1111/j.1651-2227.1986.tb10356.x. [DOI] [PubMed] [Google Scholar]
  3. Kaplan S. L., Underwood L. E., August G. P., Bell J. J., Blethen S. L., Blizzard R. M., Brown D. R., Foley T. P., Hintz R. L., Hopwood N. J. Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children. Lancet. 1986 Mar 29;1(8483):697–700. doi: 10.1016/s0140-6736(86)91098-6. [DOI] [PubMed] [Google Scholar]
  4. Milner R. D., Burns E. C. Investigation of suspected growth hormone deficiency. On behalf of the Health Services Human Growth Hormone Committee. Arch Dis Child. 1982 Dec;57(12):944–947. doi: 10.1136/adc.57.12.944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Milner R. D. Clinical experience of somatrem: UK preliminary report. Acta Paediatr Scand Suppl. 1986;325:25–28. doi: 10.1111/j.1651-2227.1986.tb10359.x. [DOI] [PubMed] [Google Scholar]
  6. Milner R. D. Growth hormone 1985. Br Med J (Clin Res Ed) 1985 Dec 7;291(6509):1593–1594. doi: 10.1136/bmj.291.6509.1593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Takano K., Shizume K. Clinical experience with somatrem in Japan. Acta Paediatr Scand Suppl. 1986;325:19–24. doi: 10.1111/j.1651-2227.1986.tb10358.x. [DOI] [PubMed] [Google Scholar]
  8. Tanner J. M., Whitehouse R. H., Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II. Arch Dis Child. 1966 Dec;41(220):613–635. doi: 10.1136/adc.41.220.613. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES